ABUS vs WVE: stock comparison and AI forecast
Arbutus Biopharma Corp (ABUS) and Wave Life Sciences, Inc. (WVE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABUS Arbutus Biopharma Corp
- Price
- $3.88 -11.8% · 6M
- Market Cap
- $768M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
WVE Wave Life Sciences, Inc.
- Price
- $3.59 -49.2% · 6M
- Market Cap
- $707M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ABUS and WVE have similar market capitalizations ($768M and $707M).
- Over the last six months ABUS returned -11.8% and WVE -49.2%.
- WVE carries 0.26 times debt per unit of equity, against 0.06 times for ABUS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABUS | WVE |
|---|---|---|
| Market Cap | $768M | $707M |
| P/B Ratio | 2.97x | 1.76x |
| EPS | $-0.21 | $-1.19 |
| Book Value/Share | $1.31 | $2.04 |
| Revenue/Share | $0.92 | $0.59 |
| FCF/Share | – | $-1.06 |
Profitability & Margins
| Metric | ABUS | WVE |
|---|---|---|
| ROE | – | -52.4% |
| ROA | – | -41.5% |
| ROIC | 55.0% | -50.2% |
| Operating Margin | 82.0% | -194.9% |
| Net Margin | – | -180.3% |
| EBT Margin | 84.6% | -180.3% |
| Tax Rate | 0.0% | 0.0% |
Financial Health
| Metric | ABUS | WVE |
|---|---|---|
| Current Ratio | 81.42x | 8.38x |
| D/E Ratio | 0.06x | 0.26x |
| Financial Leverage | 1.06x | 1.26x |
| Interest Coverage | – | -826.5x |
| Working Capital | $271M | $404M |
Cash Flow
| Metric | ABUS | WVE |
|---|---|---|
| Operating Cash Flow | -$25M | -$207M |
| Free Cash Flow | – | -$208M |
| Capital Spending | – | -$1M |
| FCF/Sales | – | -178.4% |
| CapEx/Sales | – | 1.1% |
Operational Efficiency
| Metric | ABUS | WVE |
|---|---|---|
| Asset Turnover | 0.66x | 0.23x |
| Receivables Turnover | 492.5x | 9.7x |
| Fixed Assets Turnover | 18172.0x | 18.7x |
| Days Sales Outstanding | 1 days | 38 days |
Income Statement
| Metric | ABUS | WVE |
|---|---|---|
| Total Revenue | $182M | $117M |
| Operating Income | $149M | -$228M |
| Net Income | – | -$211M |
| R&D Expense | $18M | $205M |
Dividend & Shareholder Information
| Metric | ABUS | WVE |
|---|---|---|
| Shares Outstanding | 198M | 197M |
ABUS vs WVE: stock comparison and AI forecast
Which is bigger, ABUS or WVE?
ABUS and WVE have similar market capitalizations ($768M and $707M).
Which stock performed better over the last six months, ABUS or WVE?
Over the last six months ABUS returned -11.8% and WVE -49.2%.
Which one does Intratio's AI model rank higher, ABUS or WVE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.